NeuroSense Therapeutics NRSN
NASDAQ NRSN
$6.62 +0.27 (+4.25%)
At close: Sep 21, 2026 · 4:00 PM EDT

NeuroSense Therapeutics (NRSN) Income towards Parent Company (2021 - 2024)

NeuroSense Therapeutics' (NRSN) quarterly Income towards Parent Company came in at -$1.8 million in Q4 2024, up 84.67% year-over-year from -$959004.6 in Q1 2024, and up 15.95% quarter-over-quarter from -$2.1 million in Q3 2024.

Analysis

NeuroSense Therapeutics (NRSN) Income towards Parent Company (2021 - 2024) Analysis & Trends

NeuroSense Therapeutics has disclosed Income towards Parent Company across 4 years of filings, most recently posting -$1.8 million for Q4 2024.

  • In Q4 2024, Income towards Parent Company rose 84.67% year-over-year to -$1.8 million; the TTM figure through Dec 2024 stood at -$9.9 million (up 31.42% YoY), while the FY2025 annual figure was -$11.1 million, down 8.58% from the prior year.
  • Income towards Parent Company came in at -$1.8 million for Q4 2024 at NeuroSense Therapeutics, up from -$2.1 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $4.9 million in Q4 2021 to a low of -$11.6 million in Q4 2023.
  • Average Income towards Parent Company over 4 years is -$2.3 million, with a median of -$2.6 million recorded in 2023.
  • The largest YoY upside for Income towards Parent Company was 150.03% in 2023 against a maximum downside of 626.15% in 2023.
  • Over 4 years, Income towards Parent Company stood at $4.9 million in 2021, then plunged by 132.66% to -$1.6 million in 2022, then slumped by 626.15% to -$11.6 million in 2023, then soared by 84.67% to -$1.8 million in 2024.
  • Per Business Quant data, the three most recent Income towards Parent Company figures were -$1.8 million in Q4 2024, -$2.1 million in Q3 2024, and -$3.0 million in Q2 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn
10 NeuroSense Therapeutics 8.09 Mn 7.88 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -1.77 Mn
Sep 30, 2024 -2.11 Mn
Jun 30, 2024 -3.03 Mn
Mar 31, 2024 -2.99 Mn
Dec 31, 2023 -11.55 Mn
Sep 30, 2023 1.49 Mn
Jun 30, 2023 -1.76 Mn
Mar 31, 2023 -2.62 Mn
Dec 31, 2022 -1.59 Mn
Sep 30, 2022 -2.97 Mn
Jun 30, 2022 -3.41 Mn
Mar 31, 2022 -2.67 Mn
Dec 31, 2021 4.87 Mn
API Access

NeuroSense Therapeutics Income towards Parent Company API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-towards-parent-company&ticker=NRSN&period=max&api_key=YOUR_API_KEY